Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
127.00    -0.60 (-0.47%)
Bid:
126.60
Ask:
128.00
Spread: 1.40 (1.106%)
Market Cap: £528.84m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Trading Update

31 Jul 2024 07:00

RNS Number : 4227Y
James Halstead PLC
31 July 2024
 

 

31 July 2024

 

 

JAMES HALSTEAD PLC (the "Company")

Trading Update

James Halstead plc, the commercial flooring manufacturer and international distributor, is providing the following trading update ahead of its results for the year ended 30 June 2024.

 

The Company is fully confident of exceeding the prior year comparatives for profit, cash levels and dividend, with improved profitability seen in the first half continuing into H2.

 

The Company sells, for the most part, commercial flooring across the world and has seen continued confidence in the segment of resilient sheet flooring that is sold into the healthcare, education and other institutional sectors. Regionally sales into the Middle East and the Americas have been particularly buoyant. Some of the Company's products are focused on domestic sectors and performance of these products have been weaker in several territories - the UK and Europe being the most significant.

 

Notwithstanding this drag on performance the Group's productive output, gains on product mix and cost control of overheads have bolstered margins.

 

There have been gains on lower raw material pricing although energy costs, principally electricity, remain high. Notwithstanding the fall in raw materials costs during the year these input costs, in general, are around 50% ahead of June 2020 levels.

 

Operationally, the widely reported disruption to shipping in the Red Sea has lengthened delivery times and increased costs across the sector, which is particularly difficult for our APAC markets. As a result stock in transit has increased and in response we are holding stocks in the our overseas marketplaces at higher than normal levels.

 

 

In summary, profit before tax will be at record levels and in line with (upwardly revised) market expectations.

 

The Company expects to announce its results for the year ended 30 June 2024 on 1 October 2024.

 

 

The Company also announces that its Nominated Adviser and Broker has changed its name to Panmure Liberum Limited following completion of its own corporate merger.

 

 

 

Enquiries:

 

James Halstead plc

Tel: 0161 767 2500

Mark Halstead, Chief Executive

Gordon Oliver, Finance Director

 

Hudson Sandler

Tel: 020 7796 4133

Nick Lyon / Nick Moore

Panmure Liberum (Nomad and Joint Broker)

Tel: 020 7886 2500

Ed Mansfield / Tom Scrivens

Zeus (Joint Broker)

Ben Thorne / Fraser Marshall

 

Tel: 020 3829 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKKBKDBKDDON
Date   Source Headline
25th Jan 20107:00 amRNSPre-close Trading Statement
4th Jan 20107:00 amRNSBlocklisting Interim Review
31st Dec 20097:00 amRNSTotal Voting Rights
18th Dec 20094:00 pmRNSAnnual Report and Accounts
14th Dec 200911:30 amRNSDirector's shareholding
10th Dec 20093:00 pmRNSDirector's shareholding
7th Dec 20091:50 pmRNSDirector's shareholding
4th Dec 20091:00 pmRNSDividend Declaration
4th Dec 20097:00 amRNSAGM Statement
12th Oct 200912:00 pmRNSDirector/PDMR Shareholding
29th Sep 20097:00 amRNSPreliminary Results
17th Sep 200911:37 amRNSNotice of Preliminary Results
29th Jul 20097:00 amRNSPre-Close Trading Update
1st Jul 200912:30 pmRNSBlocklisting Interim Review
30th Mar 20094:45 pmRNSDividend Declaration - Correction
30th Mar 20097:00 amRNSInterim Results
17th Mar 20093:12 pmRNSNotice of Results
26th Feb 20098:00 amRNSBlocklisting Interim Review
28th Jan 20097:00 amRNSPre-close Trading Statement
22nd Dec 200812:30 pmRNSAnnual Report and Accounts
10th Dec 20087:00 amRNSAGM Statement
8th Oct 200812:00 pmRNSDirector/PDMR Shareholding
6th Oct 20085:00 pmRNSDirector/PDMR Shareholding
30th Sep 20085:08 pmRNSDirectors' Dealings
30th Sep 20087:00 amRNSFinal Results
24th Sep 20087:00 amRNSExecutive Board Appointment
19th Sep 20084:50 pmRNSSecond Price Monitoring Extn
19th Sep 20084:35 pmRNSPrice Monitoring Extension
16th Sep 200810:00 amRNSNotice of Results
4th Sep 20087:00 amRNSNotice of Results
31st Jul 20087:00 amRNSTotal Voting Rights
3rd Jul 20081:00 pmRNSBlocklisting Interim Review
1st Jul 20087:00 amRNSTrading Statement
11th Jun 20081:00 pmRNSAdditional Listing
30th May 200810:58 amRNSTotal Voting Rights
14th May 20087:00 amRNSDirector/PDMR Shareholding
31st Mar 20087:00 amRNSInterim Results
1st Feb 20084:50 pmRNSTotal Voting Rights
31st Jan 20083:49 pmRNSAdditional Listing
30th Jan 20082:16 pmRNSDirector/PDMR Shareholding
28th Jan 20087:00 amRNSPre-close Trading Update
23rd Jan 20084:31 pmRNSBlock Listing Returns
15th Jan 20081:11 pmRNSDirector/PDMR Shareholding
7th Jan 200812:43 pmRNSDirector/PDMR Shareholding
7th Dec 20077:01 amRNSAGM Statement
15th Nov 200710:56 amRNSAnnual Report and Accounts
1st Oct 20077:01 amRNSFinal Results
10th Sep 20079:38 amRNSNotice of Results
31st Aug 20073:33 pmRNSTotal Voting Rights
23rd Aug 20071:21 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.